Isolation of Cellular Material Under Microscopic Visualization

Liotta *et al.* (NCI)
Serial No. 08/203,780 filed 01 Mar 1994, issued as U.S. Patent No. 5,843,644; Serial No. 08/544,388 filed 10 Oct 1995, issued as U.S. Patent No. 5,843,657; Serial No. 08/882,699 filed 25 Jun 1997; Serial No. 08/925,894 filed 08 Sep 1997, issued as U.S. Patent No. 6,010,888; Serial No. 09/388,805 filed 02 Sep 1999
Licensing Contact: J. P. Kim; 301/496–7056 ext. 264; e-mail: kimj@od.nih.gov

The present technology provides methods and devices for the isolation and analysis of cellular samples on a molecular or genetic level. More particularly, the invention relates to methods and devices for the microdissection, for example, utilizing laser capture microdissection (LCM), and the diagnosis and analysis of cellular samples which may be used in combination with a number of different technologies that allow for analysis of enzymes, antigens, mRNA, DNA, and the like from pure populations or subpopulations of particular cell types.

Nucleic Acid Constructs Containing HIV Genes with Mutated Inhibitory/Instability Regions and Methods of Using Same

George N. Pavlakis, Barbara K. Felber (NCI)
Serial No. 07/858,747 filed 27 Mar 1992; U.S. Patent 5,972,596 issued 26 Oct 1999; U.S. Patent 5,965,726 issued 12 Oct 1999; Serial No. 09/414,117 filed 08 Oct 1999; PCT/US93/02908
Licensing Contact: Carol Salata; 301/496–7735 ext. 232; e-mail: salatac@od.nih.gov

This invention describes methodology for modifying the inhibitory/instability sequences (INS) of mRNA by making multiple nucleotide substitutions without altering the coding capacity of the mRNA of interest. Mutating INS allows for or increases the expression of genes that would otherwise have not been expressed or would have been poorly expressed because of the INS normally present on the mRNA transcript. This novel approach also improves the stability of the mRNA. These methods can be used to increase the production of protein from many genes producing, for example, growth hormone, interferons, interleukins, and HIV Gag and env. DNA constructs are described which encode Gag protein which is highly expressed and does not require HIV rev for production. Thus it is a potentially useful HIV DNA vaccine. Assays have also been developed to facilitate detection of the boundaries of INS sequences of any mRNA.

Dated: September 20, 2000.

Jack Spiegel,

Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health.

[FR Doc. 00–25175 Filed 9–29–00; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, Public Health Service, DHHS.

ACTION: Notice.

SUMMARY: The invention listed below is owned by an agency of the U.S. Government and is available for licensing in the U.S. in accordance with 35 U.S.C. 207 to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing.

ADDRESS: Licensing information and copies of the U.S. patent application listed below may be obtained by contacting Susan S. Rucker, J.D., at the Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852–3804; telephone: 301/496–7056 ext. 245; fax: 301/402–0220; e-mail: ruckers@od.nih.gov. A signed Confidential Disclosure Agreement will be required to receive a copy of the patent application.

HGF–SF Monoclonal Antibody Combinations

B Cao, S Koochekpou, M Oskarsson, D Bjurickovic, M Fivash, R Fisher and GR Vande Woude (NCI)
Serial No. 60/164,173 filed 09 Nov 1999

The invention described and claimed in this application relates to a composition which comprises a combination of two or more antibodies which specifically bind one or more epitopes of the growth factor known as hepatocyte growth factor/scatter factor (HGF/SF) which is able to inhibit HGF/SF signaling. In particular, the antibodies which specifically bind to HGF/SF are monoclonal antibodies. Hepatocyte Growth Factor (HGF) activates migration and proliferation of endothelial cells and is angiogenic, acting through the tyrosine kinase receptor encoded by the Met protooncogene. In addition, HGF/SF displays a unique feature in inducing ''branching morphogenesis'', a complex program of proliferation and motogenesis in a number of different cell types. Moreover, HGF is involved in the invasive behavior of several tumor cells both in vivo and in vitro. This combination of antibodies may be useful in drug screening assays, detection of HGF/SF expression or activity or in treating HGF/SF related diseases such as cancer.

Dated: September 21, 2000.

Jack Spiegel,

Director, Division of Technology Development and Transfer Office of Technology Transfer National Institutes of Health.

[FR Doc. 00–25176 Filed 9–29–00; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Notice of Meeting: Chronic Fatigue Syndrome Coordinating Committee

In accordance with section 10(a) of the Federal Advisory Committee Act, as amended (5 U.S.C., Appendix 2), notice is hereby given of a meeting of the Chronic Fatigue Syndrome Coordinating Committee.

Name: Chronic Fatigue Syndrome Coordinating Committee

Time and Date: Wednesday, October 25, 2000, from 9 a.m. to 4:30 p.m.

Place: Hubert H. Humphrey Building, Room 800, 200 Independence Avenue, SW., Washington, DC 20201.

Status: Open to the public, limited only by the space available. The meeting room will accommodate approximately 100 people. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting.

Notice: In the interest of security, the Department has instituted stringent procedures for entrance to the Hubert H. Humphrey Building by non-government employees. Thus, persons without a government identification card will need to provide a photo ID and must know the subject and room number of the meeting in order to be admitted into the building. Visitors must use the Independence Avenue entrance.

Purpose: The Committee is charged with providing advice to the Secretary, the Assistant Secretary for Health, and the Commissioner, Social Security Administration (SSA), to assure interagency coordination and communication regarding chronic fatigue syndrome (CFS) research and

other related issues; facilitating increased DHHS and agency awareness of CFS research and educational needs; developing complementary research programs that minimize overlap; identifying opportunities for collaborative and/or coordinated efforts in research and education; and developing informed responses to constituency groups regarding DHHS and SSA efforts and progress.

Matters To Be Discussed: The meeting will include a discussion of the CFS State of the Science Conference held October 23–24, 2000; progress report from the Name Change Working Group; update on current Federal activities; and identification of areas for future focus for the CFSCC. Public comments will be received at the meeting on two topics of interest to the Committee: (1) Lack of access to social services and (2) insensitive medical care. Persons wishing to make oral comments on these topics either in person or via video should notify the contact person listed below no later than COB on October 17, 2000. Five minutes will be allotted for each statement; both printed and electronic copies are requested for the record.

Contact Person for More Information: Janice C. Ramsden, Executive Secretary, CFSCC, Office of the Principal Deputy Director, NIH, Building 1, Room 333, 1 Center Drive, MSC 0159, Bethesda, Maryland 20892–0159, e-mail *jr52h@nih.gov* or telephone 301–496–0959.

Dated: September 22, 2000.

LaVerne Stringfield,

Director, Office of Federal Advisory Committee Policy.

[FR Doc. 00–25163 Filed 9–29–00; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The contract proposals and the discussions could disclose confidential trade secrets or commercial property such patentable material, and personal information concerning individuals associated with the contract proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Institute of Allergy and Infectious Diseases Special Emphasis Panel.

Dates: October 30, 2000.

Time: 8:30 AM to 4:00 PM.

Agenda: To review and evaluate contract proposals.

Place: Holiday Inn, 5520 Wisconsin Avenue, Chevy Chase, MD 20815.

Contact Person: Edward W. Schroder, PHD, Scientific Review Administrator, Scientific Review Program, Division of Extramural Activities, NIAID, NIH, Room 2156, 6700–B Rockledge Drive, MSC 7610, Bethesda, MD 20892–7610, 301–496–2550.

(Catalogue of Federal Domestic Assistance Program Nos. 93.855, Allergy Immunology, and Transplantation Research; 93.856, Microbiology and Infectious Diseases Research, National Institutes of Health, HHS)

Dated: September 21, 2000.

LaVerne Y. Stringfield,

Director, Office of Federal Advisory Committee Policy.

[FR Doc. 00–25156 Filed 9–29–00; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Allergy and Infectious Diseases; Notice of Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given on the following meeting.

The meeting will be open to the public as indicated below, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: Microbiology and Infectious Diseases Research Committee.

Dates: October 4–5, 2000.

Open: October 4, 2000, 9:00 AM to 10:00 AM.

Agenda: Reports from various Institute staff.

Place: One Washington Circle Hotel, Conference Center, One Washington Circle, DC 20037.

Closed: October 4, 2000, 9:00 AM to adjournment on October 5, 2000.

Agenda: To review and evaluate grant applications.

Place: One Washington Circle Hotel, Conference Center, One Washington Circle, DC 20037.

Contact Person: Gary S. Madonna, PhD, Scientific Review Administrator, Scientific Review Program, Division of Extramural Activities, NIAID, NIH, Room 2217, 6700–B Rockledge Drive, MSC 7610, Bethesda, MD 20892–7610, 301–496–2550.

This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle.

(Catalogue of Federal Domestic Assistance Program Nos. 93.855, Allergy, Immunology, and Transplantation Research; 93.856, Microbiology and Infectious Diseases Research, National Institutes of Health, HHS)

Dated: September 21, 2000.

LaVerne Y. Stringfield,

Director, Office of Federal Advisory Committee Policy.

[FR Doc. 00–25157 Filed 9–29–00; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute on Deafness and Other Communication Disorders; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Institute on Deafness and Other Communications Disorders Special Emphasis Panel.

Dates: November 14–15, 2000.

Time: 8 AM to 12 PM.

Agenda: To review and evaluate grant applications.

Place: The Virginian Suites, 1500 Arlington Blvd., Arlington, VA 22209.

Contact Person: Stanley C. Oaks, Jr., PhD, Scientific Review Branch, Division of Extramural Research, Executive Plaza South, Room 400C, 6120 Executive Blvd., Bethesda, MD 20892–7180, 301–496–8683.

(Catalogue of Federal Domestic Assistance Program Nos. 93.173, Biological Research